None of the 29 investors followed here reported a position in GHRS in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a GHRS trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for GHRS.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 23.3 | -5.2 | -5.3 | 46.0 | 16.9 | 12.0 | 4.4 | -3.9 | -13.0 | -17.4 | +52.6% | ||
| 2025 | 51.4 | -4.4 | 8.9 | -13.5 | 26.1 | 1.3 | 17.8 | -6.0 | 5.9 | 0.1 | 5.9 | -16.2 | +81.4% |
| 2024 | 30.9 | 17.0 | 20.0 | 2.8 | 28.6 | -17.2 | 6.3 | -15.3 | -36.3 | 21.1 | 10.2 | -21.6 | +20.7% |
| 2023 | -8.5 | 7.8 | -16.6 | 5.1 | 33.3 | 5.9 | 10.8 | -19.2 | -5.5 | -27.3 | -14.6 | -7.1 | −40.3% |
| 2022 | -27.2 | -2.8 | 10.8 | -20.4 | -31.2 | -0.4 | 11.8 | 39.3 | -25.3 | -12.4 | 7.5 | -11.2 | −58.3% |
| 2021 | -9.3 | 11.0 | 0.9 | 14.7 | 4.6 | -11.9 | +7.4% |
Buy / hold / sell counts
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.